Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2017’, provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis

The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeome Corp

AdAlta Ltd

Aeolus Pharmaceuticals Inc

Allinky Biopharma

AnaMar AB

apceth Biopharma GmbH

Asahi Kasei Pharma Corp

aTyr Pharma Inc

Biogen Inc

Bioneer Corp

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Chiesi Farmaceutici SpA

Compugen Ltd

Cynata Therapeutics Ltd

F. Hoffmann-La Roche Ltd

FibroGen Inc

FibroStatin SL

Galapagos NV

GenKyoTex SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Global Blood Therapeutics Inc

iBio Inc

Inventiva

Isarna Therapeutics GmbH

Kadmon Corp LLC

Kasiak Research Pvt Ltd

Kyorin Pharmaceutical Co Ltd

Lung Therapeutics Inc

Merck & Co Inc

Miragen Therapeutics Inc

Mission Therapeutics Ltd

MorphoSys AG

Novartis AG

Nuevolution AB

Nuformix Ltd

Pharmaxis Ltd

Promedior Inc

ProMetic Life Sciences Inc

Pulmatrix Inc

Re-Pharm Ltd

Redx Pharma Plc

Respira Therapeutics Inc

Ribomic Inc

Saje Pharma LLC

Samumed LLC

Sanofi

Sorrento Therapeutics Inc

SPR Biosciences LLC

Therabron Therapeutics Inc

Unity Biotechnology Inc

Vicore Pharma AB

Yuhan Corp

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Idiopathic Pulmonary Fibrosis - Overview 6

Idiopathic Pulmonary Fibrosis - Therapeutics Development 7

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 22

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 36

Idiopathic Pulmonary Fibrosis - Drug Profiles 61

Idiopathic Pulmonary Fibrosis - Dormant Projects 251

Idiopathic Pulmonary Fibrosis - Discontinued Products 254

Idiopathic Pulmonary Fibrosis - Product Development Milestones 255

Appendix 266

List of Tables

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Abeome Corp, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by AdAlta Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Aeolus Pharmaceuticals Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Allinky Biopharma, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by AnaMar AB, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by apceth Biopharma GmbH, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Asahi Kasei Pharma Corp, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by aTyr Pharma Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Biogen Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Bioneer Corp, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Bristol-Myers Squibb Co, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Celgene Corp, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Celldex Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Chiesi Farmaceutici SpA, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Compugen Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Cynata Therapeutics Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by FibroGen Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by FibroStatin SL, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Galapagos NV, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by GenKyoTex SA, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by GlaxoSmithKline Plc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Global Blood Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by iBio Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Inventiva, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Isarna Therapeutics GmbH, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Kadmon Corp LLC, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Kasiak Research Pvt Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Lung Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Merck & Co Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Miragen Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Mission Therapeutics Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by MorphoSys AG, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Novartis AG, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Nuevolution AB, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Nuformix Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Pharmaxis Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Promedior Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by ProMetic Life Sciences Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Pulmatrix Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Re-Pharm Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Redx Pharma Plc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Respira Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Ribomic Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Saje Pharma LLC, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Samumed LLC, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Sanofi, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Sorrento Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by SPR Biosciences LLC, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Therabron Therapeutics Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Unity Biotechnology Inc, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Vicore Pharma AB, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Yuhan Corp, H2 2017

Idiopathic Pulmonary Fibrosis – Pipeline by Zai Lab Ltd, H2 2017

Idiopathic Pulmonary Fibrosis – Dormant Projects, H2 2017

Idiopathic Pulmonary Fibrosis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Idiopathic Pulmonary Fibrosis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Idiopathic Pulmonary Fibrosis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports